Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2009-01-14
2010-10-26
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S238000
Reexamination Certificate
active
07820669
ABSTRACT:
The compounds of a certain formula (1),in which R1, R2, R3 and R9 have the meanings as given in the description, are novel effective PDE4 inhibitors.
REFERENCES:
patent: 5267027 (1993-11-01), Ugaki et al.
patent: 5434149 (1995-07-01), Jonas et al.
patent: 5747489 (1998-05-01), Jonas et al.
patent: 5859008 (1999-01-01), Jonas et al.
patent: 6103718 (2000-08-01), Sterk
patent: 6255303 (2001-07-01), Sterk et al.
patent: 6380196 (2002-04-01), Ulrich et al.
patent: 6399611 (2002-06-01), Jonas et al.
patent: 6544993 (2003-04-01), Sterk
patent: 6756371 (2004-06-01), Sterk
patent: 6933296 (2005-08-01), Sterk
patent: 6953853 (2005-10-01), Grundler et al.
patent: 7022696 (2006-04-01), Grundler et al.
patent: 2004/0127707 (2004-07-01), Sterk
patent: 2006/0094710 (2006-05-01), Sterk
patent: 2006/0160813 (2006-07-01), Sterk
patent: 2006/0166995 (2006-07-01), Sterk
patent: 2006/0167001 (2006-07-01), Sterk
patent: 19604388 (1997-08-01), None
patent: 0539806 (1993-05-01), None
patent: 0618201 (1994-10-01), None
patent: 0723962 (1996-07-01), None
patent: 0738715 (1996-10-01), None
patent: 0763534 (1997-03-01), None
patent: 9307146 (1993-04-01), None
patent: 0119818 (2001-03-01), None
patent: 0130766 (2001-05-01), None
patent: 0130777 (2001-05-01), None
patent: 0194319 (2001-12-01), None
patent: 02064584 (2002-08-01), None
patent: 02085885 (2002-10-01), None
patent: 02085906 (2002-10-01), None
patent: 03032993 (2003-04-01), None
patent: 2004017957 (2004-03-01), None
patent: 2004017974 (2004-03-01), None
patent: 2004018449 (2004-03-01), None
patent: 2004018450 (2004-03-01), None
patent: 2004018451 (2004-03-01), None
patent: WO 2004017974 (2004-03-01), None
patent: WO 2004018451 (2004-03-01), None
patent: 2005075437 (2005-08-01), None
patent: 2005075457 (2005-08-01), None
Dyke, et al., Exp. Opin. Invest. Drugs 8:1301-1325 (1999).
Hanifin, et al., J. Investigative Dermatology, 107(1):51-56 (1996).
MacKenzie, Alergology International (2004) 53:101-110.
Barnes, P.J., “Chronic obstructive pulmonary disease *12: New treatments for COPD,” Thorax, vol. 58:9, pp. 803-808 (Sep. 2003).
Baumer, W. et al., “Highly selective Phosphodiesterase 4 Inhibitors for the Treatment of Allergic Skin Diseases and Psoriasis,” Inflammation & Allergy Drug Targets, vol. 6, Issue 1, pp. 17-26 (Mar. 2007)..
Coates, W.J. et al., “1,4-Bis(3-oxo-2,3-dihydropyridazin-6-yl)benzene Analogues: Potent Phosphodiesterase Inhibitors and Inodilators,” J. Med. Chem., vol. 33, pp. 1735-1741 (1990).
Dyke, H. et al., “The therapeutic potential of PDE4 inhibitors,” Expert Opinion on Investigational Drugs, vol. 8, issue 9, pp. 1301-1325 (1999).
European Respiratory Society, Feb. 13, 2007.
Grootendorst, D.C. et al., Current Opinion in Allergy and Clinical Immunology, vol. 2, pp. 61-67 (2002).
Hanifin, J.M. et al., “Type 4 Phosphodiesterase Inhibitors Have Clinical and In Vitro Anti-inflammatory Effects in Atopic Dermatitis,” Journal of Investigative Dermatology, vol. 107, pp. 51-56 (1996).
Kawasaki, H. et al., “The Phosphodiesterase 4 Inhibitor Prevents Antigen-induced Biphasic Nasal Obstruction in Brown Norway Rats,” Allergology International, vol. 54, No. 3, pp. 427-433 (2005).
Lipworth, B.J., “Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease,” The Lancet, vol. 365, pp. 167-175 (2005).
Mackenzie, S.J., “Phosphodiesterase 4 cAMP phosphodiesterases as targets for novel anti-inflammatory therapeutics,” Allergology International, vol. 53, pp. 101-110 (2004).
Norman, P., “PDE4 inhibitors 2001. Patent and literature activity 2000-September 2001,” Expert Opinion on Therapeutic Patents, vol. 12, No. 1, pp. 93-111 (2002).
Sasaki, K., Inflammation Research, vol. 53, pp. 031-037 (2004).
Souness, J.E. et al., “Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors,” Immunopharmacology, vol. 47, pp. 127-162 (2000).
Van der Mey, M. et al., “Novel Selective PDE4 Inhibitors. 3. In Vivo Antiinflammatory Activity of a New Series of N-Substituted cis-Tetra- and cis-Hexahydrophthalazinones,” J. Med. Chem., vol. 45, No. 12, pp. 2520-2525 (2002).
Van der Mey, M. et al., “Novel Selective Phosphodiesterase (PDE4) Inhibitors. 4. Resolution, Absolute Configuration, and PDE4 Inhibitory Activity of cis-Tetra- and cis-Hexahydrophthalazinones,” J. Med. Chem., vol. 45, No. 12, pp. 2526-2533 (2002).
Van der Mey, M. et al., “Novel Selective PDE4 Inhibitors. 1. Synthesis, Structure-Activity Relationships, and Molecular Modeling of 4-(3,4-Dimethoxyphenyl)-2H-phthalazin-1-ones and Analogues,” J. Med. Chem., vol. 44, No. 16, pp. 2511-2522 (2001).
Van der Mey, M. et al., “Novel Selective PDE4 Inhibitors. 2. Synthesis and Structure-Activity Relationships of 4-Aryl-Substituted cis-Tetra- and cis-Hexahydrophthalazinones,” J. Med. Chem., vol. 44, No. 16, pp. 2523-2535 (2001).
Menge Wiro M. P. B.
Sterk Geert Jan
Goldberg Joshua B.
Jaisle Cecilia M
McGee Sheldon M.
NYCOMED GmbH
The Nath Law Group
LandOfFree
2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4172715